<DOC>
	<DOC>NCT02880189</DOC>
	<brief_summary>This study is designed to investigate the impact of weight loss achieved with the IGB on NASH with early fibrosis in a select cohort of patients with obesity preselected to have a high pre-test probability of having NASH with early fibrosis based on MRE-Hepatogram. In addition, this study will explore potential non-invasive imaging criteria for NASH and early fibrosis using EUS-Elastography.</brief_summary>
	<brief_title>EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Patients diagnosed with Nonalcoholic Steatohepatitis with early evidence of fibrosis as seen on MREhepatogram Referred clinically for an intragastric balloon placement for weight loss Women who are pregnant or plan to be pregnant or are breastfeeding Previous history of gastric surgery Current or recent (within 6 months) gastric or duodenal ulcers Gastroparesis Liver cirrhosis Coagulopathy or active use of coagulation Inability to provide a written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Obesity NOS</keyword>
	<keyword>NASH</keyword>
	<keyword>NASH with Fibrosis</keyword>
	<keyword>Intragastric Balloon</keyword>
	<keyword>ORBERA</keyword>
	<keyword>ORBERA Intragastric Balloon</keyword>
</DOC>